Scientists have discovered that a locally developed cancer drug, PRL3-zumab, may offer a groundbreaking treatment for two major causes of blindness: wet age-related macular degeneration and diabetic retinopathy. Pre-clinical studies showed that intravenous PRL3-zumab reduced abnormal eye blood vessel leakage by 86% more than standard eye injections, with fewer risks.
